Omexta Dosage/Direction for Use

Adults: Initial 20 mg once daily. After 2 weeks the dose may be increased to 40 mg once daily if required or hydrochlorothiazide may be added.
For patients with possible depletion of intravascular volume, particularly those with impaired renal function, Olmesartan medoxomil should be initiated in such patients under close medical supervision and consideration should be given to administering a lower initial dose of drug.
The antihypertensive effect of Olmesartan medoxomil generally is evident within 2 weeks, with a maximum reduction observed about by 8 weeks after initiating therapy.
Children and adolescents: The safety and efficacy of Olmesartan medoxomil have not been established in children and adolescents up to 18 years of age.
Geriatric: No initial dosage adjustment is required and the daily dose should not exceed 20 mg/day.
Renal impairment: The maximum dose is 20 mg once daily in mild to moderate impairment (creatinine clearance 20-60 mL/min) and not recommended in severe impairment (creatinine clearance less than 20 mL/min).
Hepatic impairment: Not recommended in patients with hepatic impairment.
Mode of administration: Olmesartan medoxomil is administered orally with or without food. It is recommended to be taken at about the same time each day.